The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study
Background and Aims. Nonalcoholic fatty liver disease is the leading cause of chronic liver disease globally and can progress to cirrhosis, liver failure, and liver cancer. Current AASLD, AGA, and ADA guidelines recommend assessment for liver fibrosis in all patients with NAFLD. Serum biomarkers for...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2024-01-01
|
| Series: | International Journal of Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2024/8877130 |
| _version_ | 1797347287735730176 |
|---|---|
| author | Michael P. Curry Edward Tam Caitlin Schneider Noha Abdelgelil Tarek Hassanien Nezam H. Afdhal |
| author_facet | Michael P. Curry Edward Tam Caitlin Schneider Noha Abdelgelil Tarek Hassanien Nezam H. Afdhal |
| author_sort | Michael P. Curry |
| collection | DOAJ |
| description | Background and Aims. Nonalcoholic fatty liver disease is the leading cause of chronic liver disease globally and can progress to cirrhosis, liver failure, and liver cancer. Current AASLD, AGA, and ADA guidelines recommend assessment for liver fibrosis in all patients with NAFLD. Serum biomarkers for fibrosis, while widely available, have notable limitations. Imaging-based noninvasive testing for liver fibrosis/cirrhosis is more accurate and is becoming more widespread. Methods. We evaluated the feasibility of a novel shear wave absolute vibroelastography (S-WAVE) modality called Velacur® for assessing liver stiffness measurement (LSM) for fibrosis and attenuation coefficient estimation (ACE) in differentiating patients with chronic liver disease from normal healthy controls. Results. Fifty-four healthy controls and 89 patients with NAFLD or cured HCV with a prior known LSM of >8 kPa were enrolled, and all subjects were evaluated with FibroScan® and Velacur®. Velacur® was able to discriminate patients with increased liver stiffness as determined by a FibroScan® score of >8 kPa from healthy controls with an AUC of 0.938 (0.88-0.96). For assessment of steatosis in NAFLD patients only, Velacur® could identify patients with steatosis from healthy controls with an AUC of 0.831 (0.777-0.880). The Velacur® scan quality assessment was superior in healthy controls, as compared to patients, and the scan quality, as assessed by the quality factor (QF) and interquartile range (IQR)/median, was affected by BMI. Velacur® was safe and well tolerated by patients, and there were no adverse events. Conclusion. Velacur® assessment of liver stiffness measurement and liver attenuation is comparable to results obtained by FibroScan® and is an alternative technology for monitoring liver fibrosis progression in patients with chronic liver disease. This trial is registered with NCT03957070. |
| first_indexed | 2024-03-08T11:45:35Z |
| format | Article |
| id | doaj.art-7d209f4e7a0a407aaafa05a669a02fa5 |
| institution | Directory Open Access Journal |
| issn | 2090-3456 |
| language | English |
| last_indexed | 2024-03-08T11:45:35Z |
| publishDate | 2024-01-01 |
| publisher | Hindawi Limited |
| record_format | Article |
| series | International Journal of Hepatology |
| spelling | doaj.art-7d209f4e7a0a407aaafa05a669a02fa52024-01-25T00:00:03ZengHindawi LimitedInternational Journal of Hepatology2090-34562024-01-01202410.1155/2024/8877130The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility StudyMichael P. Curry0Edward Tam1Caitlin Schneider2Noha Abdelgelil3Tarek Hassanien4Nezam H. Afdhal5Division of GastroenterologyPacific Gastroenterology AssociatesSonic Incytes Medical Corp.Southern California Research CenterSouthern California Research CenterDivision of GastroenterologyBackground and Aims. Nonalcoholic fatty liver disease is the leading cause of chronic liver disease globally and can progress to cirrhosis, liver failure, and liver cancer. Current AASLD, AGA, and ADA guidelines recommend assessment for liver fibrosis in all patients with NAFLD. Serum biomarkers for fibrosis, while widely available, have notable limitations. Imaging-based noninvasive testing for liver fibrosis/cirrhosis is more accurate and is becoming more widespread. Methods. We evaluated the feasibility of a novel shear wave absolute vibroelastography (S-WAVE) modality called Velacur® for assessing liver stiffness measurement (LSM) for fibrosis and attenuation coefficient estimation (ACE) in differentiating patients with chronic liver disease from normal healthy controls. Results. Fifty-four healthy controls and 89 patients with NAFLD or cured HCV with a prior known LSM of >8 kPa were enrolled, and all subjects were evaluated with FibroScan® and Velacur®. Velacur® was able to discriminate patients with increased liver stiffness as determined by a FibroScan® score of >8 kPa from healthy controls with an AUC of 0.938 (0.88-0.96). For assessment of steatosis in NAFLD patients only, Velacur® could identify patients with steatosis from healthy controls with an AUC of 0.831 (0.777-0.880). The Velacur® scan quality assessment was superior in healthy controls, as compared to patients, and the scan quality, as assessed by the quality factor (QF) and interquartile range (IQR)/median, was affected by BMI. Velacur® was safe and well tolerated by patients, and there were no adverse events. Conclusion. Velacur® assessment of liver stiffness measurement and liver attenuation is comparable to results obtained by FibroScan® and is an alternative technology for monitoring liver fibrosis progression in patients with chronic liver disease. This trial is registered with NCT03957070.http://dx.doi.org/10.1155/2024/8877130 |
| spellingShingle | Michael P. Curry Edward Tam Caitlin Schneider Noha Abdelgelil Tarek Hassanien Nezam H. Afdhal The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study International Journal of Hepatology |
| title | The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study |
| title_full | The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study |
| title_fullStr | The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study |
| title_full_unstemmed | The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study |
| title_short | The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study |
| title_sort | use of noninvasive velacur r for discriminating between volunteers and patients with chronic liver disease a feasibility study |
| url | http://dx.doi.org/10.1155/2024/8877130 |
| work_keys_str_mv | AT michaelpcurry theuseofnoninvasivevelacurfordiscriminatingbetweenvolunteersandpatientswithchronicliverdiseaseafeasibilitystudy AT edwardtam theuseofnoninvasivevelacurfordiscriminatingbetweenvolunteersandpatientswithchronicliverdiseaseafeasibilitystudy AT caitlinschneider theuseofnoninvasivevelacurfordiscriminatingbetweenvolunteersandpatientswithchronicliverdiseaseafeasibilitystudy AT nohaabdelgelil theuseofnoninvasivevelacurfordiscriminatingbetweenvolunteersandpatientswithchronicliverdiseaseafeasibilitystudy AT tarekhassanien theuseofnoninvasivevelacurfordiscriminatingbetweenvolunteersandpatientswithchronicliverdiseaseafeasibilitystudy AT nezamhafdhal theuseofnoninvasivevelacurfordiscriminatingbetweenvolunteersandpatientswithchronicliverdiseaseafeasibilitystudy AT michaelpcurry useofnoninvasivevelacurfordiscriminatingbetweenvolunteersandpatientswithchronicliverdiseaseafeasibilitystudy AT edwardtam useofnoninvasivevelacurfordiscriminatingbetweenvolunteersandpatientswithchronicliverdiseaseafeasibilitystudy AT caitlinschneider useofnoninvasivevelacurfordiscriminatingbetweenvolunteersandpatientswithchronicliverdiseaseafeasibilitystudy AT nohaabdelgelil useofnoninvasivevelacurfordiscriminatingbetweenvolunteersandpatientswithchronicliverdiseaseafeasibilitystudy AT tarekhassanien useofnoninvasivevelacurfordiscriminatingbetweenvolunteersandpatientswithchronicliverdiseaseafeasibilitystudy AT nezamhafdhal useofnoninvasivevelacurfordiscriminatingbetweenvolunteersandpatientswithchronicliverdiseaseafeasibilitystudy |